Results 331 to 340 of about 580,532 (393)

The inflammatory and nutritional status in patients with dilated cardiomyopathy: Different impact for distinct phenogroups? [PDF]

Int J Cardiol Heart Vasc
Lerchner T, Fender A, Dobrev D, Rassaf T, Michel L.   +4 more
europepmc   +1 more source

Matrix metalloproteinase inhibition protects against junctophilin‐2 proteolysis during doxorubicin‐induced cardiotoxicity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Treatment of cancer patients with anthracyclines is known to cause dose‐dependent cardiotoxicity through several mechanisms including enhanced oxidative stress, ultimately resulting in defective excitation–contraction coupling.
Wesam Bassiouni, Brandon Y. H. Chan, Andrej Roczkowsky, Joshua W. Kranrod, Zabed Mahmud, Joseph O. Primeau, Woo Jung Cho, Howard S. Young, John M. Seubert, Richard Schulz   +9 more
wiley   +1 more source

Bioinformatics analysis of FCER1A as a key immune marker in dilated cardiomyopathy and systemic lupus erythematosus. [PDF]

Am J Clin Exp Immunol
Xu L, Wu T, Zhang W, Xiao S.
europepmc   +1 more source

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection. Experimental Approach Living myocardial slices (LMS) were obtained from explanted end‐stage heart failure ...
Jort S. A. van der Geest, Ilse R. Kelters, Bauke Arends, Willem B. van Ham, Ernest Diez Benavente, Thirza A. Lapré, Petra van der Kraak, Pim van der Harst, Arco J. Teske, Andreas Dendorfer, M. Mostafa Mokhles, Pieter A. Doevendans, Teun P. de Boer, Linda W. van Laake, Joost P. G. Sluijter, Vasco Sampaio‐Pinto   +15 more
wiley   +1 more source

Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy. [PDF]

JAMA Cardiol
Tayal U, Kallis C, Massen GM, Rossberg N, Graul EL, Quint JK.   +5 more
europepmc   +1 more source

A case report of non-lamin A/C dilated cardiomyopathy presenting in a patient with Najjar-Malouf syndrome. [PDF]

Eur Heart J Case Rep
Flury G, Arquint F.
europepmc   +1 more source

Clinical and Echocardiographic Risk Factors of Adverse Outcomes in Young Patients With Dilated Cardiomyopathy. [PDF]

Cardiovasc Ther
Li M, Liu W, Mi S, Wang M, Wang Y, Guo Q, Lian Z, Ge J.   +7 more
europepmc   +1 more source

The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy. [PDF]

Eur Heart J
Verdonschot JAJ, Fuster JJ, Walsh K, Heymans SRB.   +3 more
europepmc   +1 more source

ASlc5a6Deficient Mouse Model Reveals a Metabolically Driven Dilated Cardiomyopathy with Therapeutic Potential for Vitamin-Based Intervention

Fullerton MO, Phillips LC, Redgrave RE, Haufroid V, Merces G, Kerridge ST, Richardson GD, Mercier N, Roland D, Dewulf JP, Burn J, Bamforth SD, Phillips HM.   +12 more
europepmc   +1 more source